Neuren Pharmaceuticals Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
8
- Stock Symbol
-
NEU
- Investments
-
1
- Share Price
-
$14.77
- (As of Thursday Closing)
Neuren Pharmaceuticals General Information
Description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Contact Information
Website
www.neurenpharma.comCorporate Office
- 117 Camberwell Road, Hawthorn East
- Suite 1.01
- Melbourne, Victoria 3123
- Australia
Corporate Office
- 117 Camberwell Road, Hawthorn East
- Suite 1.01
- Melbourne, Victoria 3123
- Australia
Neuren Pharmaceuticals Stock Performance
As of 19-Nov-2026, Neuren Pharmaceuticals’s stock price is $14.77. Its current market cap is $1.87B with 127M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $14.77 | $14.90 | $7.69 - $16.99 | $1.87B | 127M | 428K | $0.11 |
Neuren Pharmaceuticals Financials Summary
As of 30-Jun-2026, Neuren Pharmaceuticals has a trailing 12-month revenue of $47.1M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,344,800 | 1,377,102 | 872,183 | 2,151,486 |
| Revenue | 47,089 | 41,647 | 140,644 | 153,927 |
| EBITDA | 10,441 | 17,264 | 113,408 | 132,387 |
| Net Income | 13,723 | 19,612 | 93,684 | 104,254 |
| Total Assets | 234,413 | 229,509 | 254,767 | 168,942 |
| Total Debt | 0 | 0 | 0 | 0 |
Neuren Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Neuren Pharmaceuticals Comparisons
Industry
Financing
Details
Neuren Pharmaceuticals Competitors (26)
One of Neuren Pharmaceuticals’s 26 competitors is ACADIA Pharmaceuticals, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| ZyVersa Therapeutics | Formerly VC-backed | Lighthouse Point, FL | ||||
| Brainstorm Cell Therapeutics | Corporation | New York, NY | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA |
Neuren Pharmaceuticals Patents
Neuren Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025903502-A0 | Method of treatment | Pending | 07-Aug-2025 | ||
| AU-2025901769-A0 | Process for preparing cyclo-glycyl-l-2-allylproline | Pending | 09-May-2025 | ||
| AU-2025901770-A0 | Process for preparing cyclo-glycyl-l-2-allylproline | Pending | 09-May-2025 | ||
| WO-2026232200-A1 | Process for preparing cyclo-glycyl-l-2-allylproline | Pending | 09-May-2025 | ||
| WO-2026232202-A1 | Process for preparing cyclo-glycyl-l-2-allylproline | Pending | 09-May-2025 |
Neuren Pharmaceuticals Signals
Neuren Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Neuren Pharmaceuticals Acquisitions (1)
Neuren Pharmaceuticals’s most recent deal was a Merger/Acquisition with Hamilton Pharmaceuticals for . The deal was made on 15-Oct-2007.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Hamilton Pharmaceuticals | 15-Oct-2007 | Merger/Acquisition | Drug Discovery |
Neuren Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.89 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Neuren Pharmaceuticals FAQs
-
When was Neuren Pharmaceuticals founded?
Neuren Pharmaceuticals was founded in 2001.
-
Where is Neuren Pharmaceuticals headquartered?
Neuren Pharmaceuticals is headquartered in Melbourne, Australia.
-
What is the size of Neuren Pharmaceuticals?
Neuren Pharmaceuticals has 8 total employees.
-
What industry is Neuren Pharmaceuticals in?
Neuren Pharmaceuticals’s primary industry is Biotechnology.
-
Is Neuren Pharmaceuticals a private or public company?
Neuren Pharmaceuticals is a Public company.
-
What is Neuren Pharmaceuticals’s stock symbol?
The ticker symbol for Neuren Pharmaceuticals is NEU.
-
What is the current stock price of Neuren Pharmaceuticals?
As of 19-Nov-2026 the stock price of Neuren Pharmaceuticals is $14.77.
-
What is the current market cap of Neuren Pharmaceuticals?
The current market capitalization of Neuren Pharmaceuticals is $1.87B.
-
What is Neuren Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Neuren Pharmaceuticals is $47.1M.
-
Who are Neuren Pharmaceuticals’s competitors?
ACADIA Pharmaceuticals, CuraSen, ZyVersa Therapeutics, Brainstorm Cell Therapeutics, and Capricor Therapeutics are some of the 26 competitors of Neuren Pharmaceuticals.
-
What is Neuren Pharmaceuticals’s annual earnings per share (EPS)?
Neuren Pharmaceuticals’s EPS for 12 months was $0.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process